Ignite Creation Date:
2024-05-06 @ 12:55 PM
Last Modification Date:
2024-10-26 @ 1:06 PM
Study NCT ID:
NCT03884465
Status:
TERMINATED
Last Update Posted:
2021-09-13
First Post:
2019-03-04
Brief Title:
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
Sponsor:
Liquidia Technologies Inc
Organization:
Liquidia Technologies Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Pulmonary Arterial Hypertension |
Keywords:
| Name | View |
|---|---|
| Pulmonary arterial hypertension | View |
| Pulmonary hypertension | View |
| PAH | View |
| PH | View |
| WHO Group 1 pulmonary arterial hypertension | View |
| WHO Group 1 pulmonary hypertension | View |
| WHO Group 1 PAH | View |
| WHO Group 1 PH | View |
| WHO Group 1 | View |
| Group 1 PAH | View |
| Group 1 PH | View |
| Idiopathic PAH | View |
| Heritable PAH | View |
| Drug induced PAH | View |
| Toxin induced PAH | View |
| Pulmonary shunt | View |
| Idiopathic pulmonary arterial hypertension | View |
| Heritable pulmonary arterial hypertension | View |
| Drug induced pulmonary arterial hypertension | View |
| Toxin induced pulmonary arterial hypertension | View |
| Connective tissue disease | View |